Research Results: The Second Dose Of AstraZeneca Did Not Increase The Risk Of Blood Clots

Ilustrasi (Photo by Mika Baumeister on Unsplash)

JAKARTA - The injection of AstraZeneca's COVID-19 vaccine does not increase the risk of rare blood clots with low platelet levels in recipients after the second dose. This is according to the results of research published on Wednesday, July 28. The results of this study have the potential to dampen a number of concerns about the side effects of the vaccine. Reported by Antara, data published in the medical journal The Lancet, found that the projected platelet level with thrombocytopenia syndrome (TTS) after the second dose of vaccine was 2.3 per million in vaccine recipients, comparable with levels typical of those seen in those not vaccinated, AstraZeneca said. Levels were 8.1 after the first dose, he continued. The study, led and funded by AstraZeneca, evaluated case reports that occurred within 14 days of the first or second dose on April 30. The assessment uses the Anglo-Swedish drugmaker's global safety database. "Unless TTS was identified after the first dose, these results support the administration of a two-dose Vaxzevria schedule, as indicated, to help provide protection against COVID-19 including against increased variants of concern. ," said AstraZeneca senior executive Mene Pangalos.

The AstraZeneca injection, discovered by the University of Oxford, is lagging behind in the vaccine race after a number of blows, including production delays, lawsuits and possible links to some severe but rare side effects, such as TTS, which are now being investigated by regulators. Europe has been investigating TTS cases since March and has found a possible link to Vaxzevria, and Johnson & Johnson single-dose injections. However, it maintains that the overall benefits of the two vaccines outweigh the risks. A total of 316 cases of TTS occurred in adults receiving the COVID-19 vaccine in the European Economic Area, authorities said on May 28.